R5655

Rebamipide hydrate

≥98% (HPLC), powder

• 别名: α-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic acid hydrate, Mucosta hydrate, OPC 12759 hydrate, Proamipide hydrate
• 经验公式（希尔记法）: C₁₉H₁₅ClN₂O₄ · xH₂O
• CAS号: 90098-04-7
• 分子量: 370.79 (anhydrous basis)
• MDL號碼: MFCD11114396
• 分類程式碼代碼: 12352200
• PubChem物質ID: 329824033
• NACRES: NA.77

属性

• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white
• 溶解度: DMSO: >5 mg/mL
• SMILES 字串: O.OC(=O)C(CC1=CC(=O)Nc2ccccc12)NC(=O)c3ccc(Cl)cc3
• InChI: 1S/C19H15ClN2O4.H2O/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15;/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26);1H2
• InChI 密鑰: WQRHVBKNEDPECA-UHFFFAOYSA-N

说明

生化／生理作用

Rebamipide is an anti-ulcer agent with free-radical scavenging and anti-inflammatory effects. It has been used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating COX-2 genes. Rebamipide significantly reduced ulcerogenesis and maintained mucosal superoxide dismutase (SOD) activity. It has also been used for the treatment of Behçet′s disease. Rebamipide may be involved in a noval mechanism to enhance tear secretion and increase mucin levels covering conjunctiva and cornea.

Rebamipide helps to reduce intestinal injury, stimulated by radiation.

安全信息

• 象形圖: GHS06
• 訊號詞: Danger
• 危險聲明: H301
• 防範說明: P264 - P270 - P301 + P310 - P405 - P501
• 危險分類: Acute Tox. 3 Oral
• 儲存類別代碼: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable
• 個人防護裝備: Eyeshields, Faceshields, Gloves, type N95 (US)